OlmesaRtan Improvement endothelial functiON with hypertension study

OlmesaRtan Improvement endothelial functiON with hypertension study - ORION study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015651

Enrollment

Registered

2014-11-11

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure with Preserved Ejection Fraction (HFpEF)

Interventions

an angiotensin II receptor blocker (ARB)

olmesartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: hypertensive HFpEF: 1. symptoms of HF, 2.normal or mildly reduced LV systolic function, LVEF >50% and LV end-diastolic volume index <97 ml/m2, 3. evidence of abnormal LV diastolic distensibility and stiffness.

Exclusion criteria

Exclusion criteria: 1. acute coronary syndrome, 2. active infectious diseases, 3. history of malignancy, 4. end-stage renal disease (estimated glomerular filtration ratio [eGFR]:<15 ml/min/1.73 m2) 4. not meeting the diagnostic criteria for HFpEF including reduced LVEF)

Design outcomes

Primary

Measure	Time frame
Vascular endothelial function assessed by reactive hyperemia peripheral arterial tonometry	—

Secondary

Measure	Time frame
Cardiac diastolic function, various biomarkers in blood	—

Countries

Japan

Contacts

Public ContactEiichiro Yamamoto

Kumamoto University Graduate School of Medical Sciences Cardiovascular Medicine

eyamamo@kumamoto-u.ac.jp096-373-5175

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026